379 related articles for article (PubMed ID: 15800680)
41. Lectin-binding patterns in normal, hyperplastic and neoplastic endometrium: the prognostic value of concanavalin A.
Sivridis E; Giatromanolaki A; Koukourakis M; Agnantis N
Virchows Arch; 2000 Jan; 436(1):52-8. PubMed ID: 10664162
[TBL] [Abstract][Full Text] [Related]
42. Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma.
Hamid AA; Mandai M; Konishi I; Nanbu K; Tsuruta Y; Kusakari T; Kariya M; Kita M; Fujii S
Cancer; 2002 Feb; 94(4):997-1005. PubMed ID: 11920468
[TBL] [Abstract][Full Text] [Related]
43. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium.
Afify AM; Craig S; Paulino AF; Stern R
Ann Diagn Pathol; 2005 Dec; 9(6):312-8. PubMed ID: 16308159
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of immunohistochemical expression of stem cell markers (NANOG and CD133) in normal, hyperplastic, and malignant endometrium.
Al-Kaabi M; Noel K; Al-Rubai AJ
J Med Life; 2022 Jan; 15(1):117-123. PubMed ID: 35186145
[TBL] [Abstract][Full Text] [Related]
45. Sialosyl-Tn expression in normal and pathological conditions of human endometrium. An immunohistochemical study.
Semczuk A; Paszkowska A; Miturski R; Skomra D; Cybulski M; Jakowicki JA; Berbec H
Pathol Res Pract; 2002; 198(9):589-95. PubMed ID: 12440781
[TBL] [Abstract][Full Text] [Related]
46. Inhibin (10.7 kD prostatic peptide) in normal, hyperplastic, and malignant human endometria: an immunohistochemical study.
Teni TR; Sampat MB; Sheth NA
J Pathol; 1992 Sep; 168(1):35-40. PubMed ID: 1453268
[TBL] [Abstract][Full Text] [Related]
47. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
Masuzawa H; Badokhon NH; Nakayama K; Konishi I; Nikaido T; Fujii S
Cancer; 1994 Oct; 74(8):2321-8. PubMed ID: 7922983
[TBL] [Abstract][Full Text] [Related]
48. Progesterone binding by human endometrial tissue during the proliferative and secretory phases of the menstrual cycle and by hyperplastic and carcinomatous endometrium.
Rodriquez J; Sen KK; Seski JC; Menon M; Johnson TR; Menon KM
Am J Obstet Gynecol; 1979 Mar; 133(6):660-5. PubMed ID: 426021
[TBL] [Abstract][Full Text] [Related]
49. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
[TBL] [Abstract][Full Text] [Related]
50. Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma.
Witek A; Paul-Samojedny M; Stojko R; Seifert B; Mazurek U
Gynecol Oncol; 2007 Aug; 106(2):407-12. PubMed ID: 17561234
[TBL] [Abstract][Full Text] [Related]
51. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical localization of metallothionein in endometrial lesions.
Ioachim EE; Kitsiou E; Carassavoglou C; Stefanaki S; Agnantis NJ
J Pathol; 2000 Jul; 191(3):269-73. PubMed ID: 10878548
[TBL] [Abstract][Full Text] [Related]
53. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
[TBL] [Abstract][Full Text] [Related]
54. Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26.
Pilka R; Domanski H; Hansson S; Eriksson P; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):641-50. PubMed ID: 15273280
[TBL] [Abstract][Full Text] [Related]
55. Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis.
Mylonas I; Makovitzky J; Richter DU; Jeschke U; Briese V; Friese K
Acta Histochem; 2003; 105(3):245-52. PubMed ID: 13677618
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
Cirpan T; Terek MC; Mgoyi L; Zekioglu O; Iscan O; Ozsaran A
Eur J Gynaecol Oncol; 2006; 27(4):389-92. PubMed ID: 17009632
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices.
Ioachim E; Kitsiou E; Charalabopoulos K; Mitselou A; Zagorianakou N; Makrydimas G; Tzioras S; Salmas M
Int J Gynecol Cancer; 2003; 13(3):344-51. PubMed ID: 12801267
[TBL] [Abstract][Full Text] [Related]
58. Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status.
Koshiyama M; Yoshida M; Konishi M; Takemura M; Yura Y; Matsushita K; Hayashi M; Tauchi K
Int J Cancer; 1997 Jun; 74(3):237-44. PubMed ID: 9221798
[TBL] [Abstract][Full Text] [Related]
59. Expression of nm23 in normal, hyperplastic and neoplastic endometrial tissues.
Brustmann H; Naudé S
Pathol Res Pract; 1999; 195(12):829-34. PubMed ID: 10631718
[TBL] [Abstract][Full Text] [Related]
60. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma.
Shroyer KR; Stephens JK; Silverberg SG; Markham N; Shroyer AL; Wilson ML; Enomoto T
Int J Gynecol Pathol; 1997 Jul; 16(3):225-32. PubMed ID: 9421087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
